Most Recent Articles by Lauren Grygotis
Mental health outcomes in patients with RA are unlikely to resolve with effective RA pharmacological disease management alone.
Intranasal esketamine in combination with oral antidepressants demonstrated significant reduction of depressive symptoms and improved overall severity of depressive illness and health-related quality of life and functioning.
The phase 3 study assessed the antipsychotic efficacy and safety of ALKS 3831 in patients with acute exacerbations of schizophrenia.
Investigators analyzed the differences in hospitalization outcomes, comorbidities, and utilization of procedures in patients with PD vs patients with PD and MDD.
Hospitals that have been under financial incentives for more than a decade vs less than 3 years do not have lower patient mortality rates.
More Articles by Lauren Grygotis
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Correctional Psychiatry: Challenges and Rewards
- Color Vision Impairment in Schizophrenia May Be Due to Medication
- Sleep Disorders Linked to Nonaffective Psychosis in Young Adults
- Lithium May Treat Children With Bipolar Disorder, but Pediatric Studies Are Lacking
- Improvement in Guidelines for Monitoring Patients Receiving Lithium Essential
- The Opioid System: The Foundation for Social Risk and Reward
- Nomophobia: The Modern-Day Pathology
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- Those Left Behind: Working With Suicide-Bereaved Families
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Influence of Family Functioning on Youth at High Risk For Psychosis
- Associations Among Gender Nonconformity, Mental Distress, and Substance Use Among High School Students
- Digital Cognitive Therapy Eases Daytime Effects of Insomnia
- Predicting Poststroke Depression: Biomarkers and Beyond
- Sexual Harassment, Assault Tied to Women's Health Issues